Growing evidence in various cancer types has shown that activated ATF6 signaling is correlated with lower OS, cancer recurrence, metastatic lesions, tumor growth, and resistance to radiation therapy and chemotherapy (Dadey et al., 2016; Higa et al., 2014), indicating that targeting ATF6 signaling might be a strategy for the treatment of cancer. Here, ATF6 is linked to neoplasm.